Peritoneal carcinomatosis as a pathway of metastatic dissemination in a patient with gastroesophageal junction cancer: case report and review

José Á. Tovar Ramírez; R. Lucano Valdés Ramos; Miguel Á. Nava Jiménez; Obed H. Grajeda Chávez; Luis Arturo Camarillo R.; Mariano Tovar Ponce; Emmanuel Gómez García; Mauricio Martínez Hurtado; Daniela Rodríguez Ramírez; Ludwigvan A. Bustamante S.

doi:10.18203/2349-2902.isj20230270

Authors

José Á. Tovar Ramírez General Surgery Department, North Central Hospital, PEMEX. Mexico City, Mexico https://orcid.org/0000-0003-2900-987X
R. Lucano Valdés Ramos General Surgery Department, Monterrey Regional Hospital, ISSSTE, Monterrey City, Mexico https://orcid.org/0000-0001-7135-9713
Miguel Á. Nava Jiménez Medicine Faculty of Guerrero University of Medicine, Acapulco City, Mexico https://orcid.org/0000-0002-6085-8717
Obed H. Grajeda Chávez General Surgery Department, North Central Hospital, PEMEX. Mexico City, Mexico https://orcid.org/0000-0001-8431-3407
Luis Arturo Camarillo R. General Surgery Department, General Zone Hospital Number 33, IMSS, Monterrey City, Mexico
Mariano Tovar Ponce General Surgery Department, Minatitlan Regional Hospital PEMEX, Veracruz, Mexico https://orcid.org/0000-0002-2770-4716
Emmanuel Gómez García General Surgery Department, Minatitlan Regional Hospital PEMEX, Veracruz, Mexico https://orcid.org/0000-0002-2770-4716
Mauricio Martínez Hurtado General Surgery Department, Minatitlan Regional Hospital PEMEX, Veracruz, Mexico https://orcid.org/0000-0003-0036-8801
Daniela Rodríguez Ramírez General Surgery Department, North Central Hospital, PEMEX. Mexico City, Mexico
Ludwigvan A. Bustamante S. General Surgery Department, North Central Hospital, PEMEX. Mexico City, Mexico https://orcid.org/0000-0001-5049-1547

DOI:

https://doi.org/10.18203/2349-2902.isj20230270

Keywords:

EC, Peritoneal carcinomatosis, Surgery, Surgical oncology

Abstract

The oesophageal adenocarcinoma is an increasing pathology in the last decade, predominantly in the western population. A characteristic of esophageal cancer (EC) and esophageal-gastric junction cancer (EGJC) is the high percent of metastatic disease at the time of diagnosis one of the main causes of death in these patients. The present case is about a 78-year-old man, diagnosed with Barrett's esophagus with high-grade dysplasia and stenosis of distal third of esophagus, during surgery we found peritoneal carcinomatosis with implants in gut and no resectably disease.

Metrics

Metrics Loading ...

References

Shiozaki H, Sudo K, Xiao L, Wadhwa R, Elimova E, Hofstetter WL, et al. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology. 2014;86:336-9.

Robb WB, Messager M, Dahan L, Mornex F, Maillard E, D’Journo XB, et al. Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone. Br J Surg. 2016;103:117-25.

Wu SG, Zhang WW, Sun JY, Li FY, Lin Q, He ZY. Patterns of Distant Metastasis Between Histological Types in Esophageal Cancer. Frontiers in Oncol. 2018;8.

Verstegen MHP, Harker M, van de Water C, van Dieren J, Hugen N, Nagtegaal ID, et al. Metastatic pattern in esophageal and gastric cancer: Influenced by site and histology. World J Gastroenterol. 2020;26(39):6037-46.

Waddell T. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open‐label phase 3 trial. Lancet Oncol. 2013;14:481-9.

Lordick F. Capecitabine and cisplatin with

or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open‐label phase 3 trial. Lancet Oncol. 2013;14:490-9.

Shah MA. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2‐negative, MET‐positive gastroesophageal adenocarcinoma: the MET Gastric randomized clinical trial. JAMA Oncol. 2017;3:620-7.

Napier KJ, Scheerer M, Misra S. Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 2014;6(5):112-20.

Kong JH, Lee J, Yi CA, Park SH, Park JO, Park YS, et al. Lung metastases in metastatic gastric cancer: pattern of lung metastases and clinical outcome. Gastric Cancer. 2011;15(3):292-8.

Shaheen O, Ghibour A, Alsaid B. Esophageal Cancer Metastases to Unexpected Sites: A Systematic Review. Gastroenterol Res Pract. 2017;1-13.

Siewert JR, Stein HJ, Feith M. Adenocarcinoma of the esophago-gastric junction. Scand J Surg. 2006;95:260-9.

Mostafa E, Ahmed, KB. Impact of diagnostic laparoscopy in the management of gastric cancer in Egyptian patients. The Egyp J Surg. 2019;38(3):394-8.

Steyerberg EW, Neville BA, Kopper LB. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol. 2006;24:4277-84.

Jiang KY, Huang H, Chen WY, Yan HJ, Zhen-Ting W, Xiao-Wen W, et al. Risk factors for LNM: A meta-analysis. World J Gastroenterol. 2021;27(8):737-50.

Allen CJ, Blumenthaler AN, Das P, Minsky BD, Blum M, Roy-Chowdhuri S, et al. Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma. World J Surg Oncol. 2020;18(1):2020.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Esophageal and Esophagogastric Junction Cancers. 2022;5.